Tae-Wook Chun, Ph.D.
HIV Immunovirology Unit
10 Center Drive
Bethesda, MD 20892
Our research program focuses on 1) delineating the role of viral reservoirs in the pathogenesis of HIV disease; 2) examining host and viral factors that contribute to the maintenance of HIV reservoirs; and 3) developing therapeutic strategies aimed at achieving durable virologic control in infected individuals in the absence of antiretroviral therapy. Our research program utilizes Bench-to-Bedside approaches. We conduct comprehensive genetic, immunologic, and virologic analyses of CD4+ and CD8+ T cells in diverse cohorts of HIV-infected individuals in order to address fundamental pathogenic questions, such as elucidating mechanisms of viral persistence, the role of the host immunity in containment of viral replication, and evaluating promising novel therapeutic agents in both ex vivo and in vivo settings. Based on findings from bench research, we also conduct phase I clinical trials in close collaboration with the NIAID HIV clinic, with the ultimate goal of developing safe, effective, and scalable therapeutic strategies that would allow HIV-infected individuals to control viral replication in the absence of daily antiretroviral drugs.
Dr. Chun received his Ph.D. from the Biochemistry, Cellular, and Molecular Biology Graduate Program from the Johns Hopkins University School of Medicine where he discovered and characterized latently infected, resting CD4+ T cells in HIV-infected individuals. He began his postdoctoral work in the Laboratory of Immunoregulation at NIAID as a research fellow in 1997. Subsequently, Dr. Chun was appointed to the position of staff scientist in 2001. Dr. Chun was selected as one of the Earl Stadtman Investigators and received a tenure track investigator position in the LIR in June 2016.
Nishimura Y, Gautam R, Chun TW, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M, Donau OK, Plishka RJ, Buckler-White A, Seaman MS, Lifson JD, Koup RA, Fauci AS, Nussenzweig MC, Martin MA. Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017;543(7646):559-563.
Chun TW, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol. 2015;16(6):584-9.
Chun TW, Murray D, Justement JS, Blazkova J, Hallahan CW, Fankuchen O, Gittens K, Benko E, Kovacs C, Moir S, Fauci AS. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc Natl Acad Sci U S A. 2014;111(36):13151-6.
Sadat MA, Moir S, Chun TW, Lusso P, Kaplan G, Wolfe L, Memoli MJ, He M, Vega H, Kim LJY, Huang Y, Hussein N, Nievas E, Mitchell R, Garofalo M, Louie A, Ireland DC, Grunes C, Cimbro R, Patel V, Holzapfel G, Salahuddin D, Bristol T, Adams D, Marciano BE, Hegde M, Li Y, Calvo KR, Stoddard J, Justement JS, Jacques J, Priel DAL, Murray D, Sun P, Kuhns DB, Boerkoel CF, Chiorini JA, Di Pasquale G, Verthelyi D, Rosenzweig SD. Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N Engl J Med. 2014;370(17):1615-1625.
Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn GH, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin NB, Madden PJ, Oden K, O'Dell SJ, Jarocki B, Shiakolas AR, Tressler RL, Doria-Rose NA, Bailer RT, Ledgerwood JE, Capparelli EV, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P, Chun TW. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med. 2016;375(21):2037-2050.
Related Scientific Focus Areas
Microbiology and Infectious Diseases
This page was last updated on August 2nd, 2017